Everest Medicines Appoints Rogers Yongqing Luo as General Manager to Lead Next Stage of Company Growth

Everest Medicines Appoints Rogers Yongqing Luo as General Manager to Lead Next Stage of Company Growth

SHANGHAI, September 18, 2022 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceuticals to address critical unmet needs in Asia Pacific markets, announced the appointment of Rogers Yongqing Luo as the company’s chief executive officer, effective immediately. Mr. Luo will also serve as executive director of Everest’s board.

Mr. Luo brings to Everest more than 25 years of experience in the healthcare industry with extensive leadership experience in clinical development, regulatory affairs and commercialization. Previously, Mr. Luo served as chairman and general manager, Greater China at Brii Biosciences and CEO of TSB Therapeutics, where he led the rapid registration approval, GMP certification and successful commercialization of the amubarvimab/romlusevimab combination, the first COVID-19 neutralizing antibody therapy in China. Previously, he was Global Vice President and General Manager of China at Gilead Sciences, where he led the clinical development, regulatory approval and successful commercial launch of eight innovative treatments, and efforts that rapidly expanded access. patients through China. Mr. Luo previously oversaw the successful launch of several high-profile drugs. He led sales, marketing, government affairs and market access functions for various leading multinational pharmaceutical companies, including Roche and Novartis, and worked two years at Novartis headquarters in Swiss.

“As Everest Medicines continues to evolve our business strategy and expand our portfolio of new products at a rapid pace, we are excited to have Rogers join the company to lead Everest into its next phase of growth by becoming a biopharmaceutical fully integrated into China“, said Mr. Wei Fu, President of Everest Medicines and CEO of CBC Group. “With a strong track record as a senior executive in both a biotech start-up and large multinational pharmaceutical companies, Rogers brings a unique set of expertise to Everest, including comprehensive scientific knowledge, proven exceptional leadership and excellent commercialization capabilities in patient access, as well as a demonstrated history of success advancing the innovative pipeline from early and late stage to commercial launch in Greater China. In particular, Rogers’ leadership will strengthen Everest’s new product development and commercial capabilities as we move toward potential approvals of our lead late-stage product candidates, including Nefecon, Xerava, etrasimod and mRNA vaccines. We look forward to leveraging Rogers’ industry leadership and expertise to drive long-term growth and success across the business. »

“I am very excited to join Everest and look forward to working with this talented, world-class team of scientists and industry professionals to build the company’s industry leadership. We will continue to advance our pipeline advanced to commercialization and with our strong balance sheet, we aim to execute synergistic business development agreements to accelerate our path to becoming an integrated biopharma,” said Rogers Yongqing Luo, Chairman and CEO of Everest Medicines. will continue to invest in our discovery platform to build an innovative therapeutic pipeline to benefit patients with unmet needs in Greater China and other Asia Pacific markets, and to create sustainable, long-term value for our shareholders. »

About drugs Everest

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address the critical unmet medical needs of patients in Asian markets. Everest Medicines’ management team has deep expertise and extensive experience in high quality clinical development, regulatory affairs, CMC, business development and operations in both China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of potentially first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune diseases, cardio-renal diseases and infectious diseases. For more information, please visit their website at www.everestmedicines.com.

Forward-looking statements:

This press release may contain statements that constitute forward-looking statements, including descriptions regarding the current intention, belief or expectations of the Company or its officers with respect to the Company’s business activities and financial condition. , which can be identified by terminology such as “will”, “expect”, “anticipate”, “future”, “intend”, “plan”, “believe”, “estimate”, ” trust” and similar statements. These forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the Company’s control and cannot be predicted. Therefore, actual results may differ from those in forward-looking statements due to various factors and assumptions, such as future changes and developments in our business, the competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives is under no obligation and does not undertake to revise any forward-looking statements to reflect new information, future events or circumstances after the date of this press release, except as required by law. .


View original content: https://www.prnewswire.com/news-releases/everest-medicines-appoints-rogers-yongqing-luo-as-chief-executive-officer-to-lead-next-stage-of-company – growth-301626689.html

SOURCE Everest Medicines

#Everest #Medicines #Appoints #Rogers #Yongqing #Luo #General #Manager #Lead #Stage #Company #Growth

Leave a Comment

Your email address will not be published.